Navigation Links
Varian Medical Systems Schedules Webcast of Investor Meeting and Fiscal Year End Review at ASTRO in San Diego, November 2, 2010
Date:10/26/2010

PALO ALTO, Calif., Oct. 26 /PRNewswire-FirstCall/ -- Varian Medical Systems (NYSE: VAR) will hold a webcast of its investor event on Tuesday, November 2 at the annual meeting of the American Society for Therapeutic Radiology and Oncology (ASTRO) in San Diego.  The meeting and presentation will be webcast beginning at 7:30 a.m. pacific time.  To access the webcast, click on http://investors.varian.com/index.php?s=19&item=148.  The meeting will include a review of fiscal year 2010 and new products and technology being featured at the company's ASTRO exhibition.

Management presentations will focus on new technologies and products and growth initiatives within the company's Oncology Systems, X-Ray Products, and emerging businesses. Management will include: Varian Medical Systems' CEO and President Tim Guertin; Executive Vice President and Oncology Systems President Dow Wilson; Senior Vice President and CFO Elisha Finney; Senior Vice President and President X-Ray Products Robert Kluge; Vice President Emerging Businesses Lester Boeh; and Investor Relations Vice President Spencer Sias.

Varian Medical Systems, Inc., of Palo Alto, California, is the world's leading manufacturer of medical devices and software for treating cancer and other medical conditions with radiotherapy, radiosurgery, proton therapy, and brachytherapy. The company supplies informatics software for managing comprehensive cancer clinics, radiotherapy centers and medical oncology practices. Varian is a premier supplier of tubes and digital detectors for X-ray imaging in medical, scientific, and industrial applications and also supplies X-ray imaging products for cargo screening and industrial inspection. Varian Medical Systems employs approximately 5,200 people who are located at manufacturing sites in North Amer
'/>"/>

SOURCE Varian Medical Systems, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. First Patient Enrolled in Europe in Ovature Phase III Ovarian Cancer Trial
2. Sunesis Pharmaceuticals Reports Preliminary SNS-595 Activity in Ovarian Cancer Clinical Trial at AACR-NCI-EORTC International Conference
3. Clinical Studies of OvaRex in Advanced Ovarian Cancer Fail to Meet Primary Endpoint
4. Northwest Biotherapeutics Conducting Ovarian Cancer Clinical Trial With DCVax(R)-L at University of Pennsylvania
5. EntreMed Commences Phase 2 Study With MKC-1 in Ovarian/Endometrial Cancers
6. BioNumerik Commences Global Phase III Ovarian Cancer Trial on Novel Anticancer Drug Candidate Known as Karenitecin(R)
7. Sunesis Pharmaceuticals Reports Positive Interim Data for SNS-595 Single-Agent Activity in Platinum-Resistant Ovarian Cancer
8. Vermillions Biomarkers Prove Beneficial in Identifying Women With Ovarian Cancer and Detecting Early-Stage Disease
9. BSI-201 Demonstrates Significant Tumor Growth Inhibition and Increased Survival Rates in Preclinical Ovarian Cancer Studies
10. BiPar Sciences Expands Phase 2 Clinical Trials of BSI-201, a Novel DNA Repair Inhibitor, in Ovarian Cancer
11. Join NPRs David Ewing Duncan, Author Jessica Queller and a Panel of Medical and Legal Experts in a 90-Minute Webcast on Genetic Testing, Genomic Medicine and Breast & Ovarian Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2015)... July 2, 2015 BGI announced today that ... Kong has been accredited by the American ... the first clinical next-generation-sequencing laboratory to receive the CAP ... highest standard in clinical laboratory practices. Complementary to the exiting ... process, and multiple ISO certifications, the CAP certification enables ...
(Date:7/2/2015)... 2, 2015 Agreement ... to HIV treatments   ViiV Healthcare ... to enable production in China of ... dolutegravir active pharmaceutical ingredient (API), and will allow ViiV Healthcare ... 50mg, marketed under the name Tivicay®) for China ...
(Date:7/1/2015)... , July 1, 2015 ContraVir Pharmaceuticals, Inc. ... the development and commercialization of targeted antiviral therapies, announced ... Inaugural Healthcare Conference taking place in New ... Le Parker Meridien Hotel. James ... of the Company,s business during his live presentation and ...
Breaking Medicine Technology:BGI Receives Accreditation from the College of American Pathologists (CAP) 2ViiV Healthcare and Desano Pharmaceuticals' Manufacturing Agreement Will Allow Competitive Supply of Dolutegravir in China and Several Developing Countries 2ViiV Healthcare and Desano Pharmaceuticals' Manufacturing Agreement Will Allow Competitive Supply of Dolutegravir in China and Several Developing Countries 3ViiV Healthcare and Desano Pharmaceuticals' Manufacturing Agreement Will Allow Competitive Supply of Dolutegravir in China and Several Developing Countries 4ViiV Healthcare and Desano Pharmaceuticals' Manufacturing Agreement Will Allow Competitive Supply of Dolutegravir in China and Several Developing Countries 5ViiV Healthcare and Desano Pharmaceuticals' Manufacturing Agreement Will Allow Competitive Supply of Dolutegravir in China and Several Developing Countries 6ContraVir to Present at Cantor Fitzgerald Inaugural Healthcare Conference 2
... Enhance Precision and Reduce High Failure Rates in ... March 16 ICON (Nasdaq: ICLR ... services to the pharmaceutical, biotechnology and medical device ... psychiatric patient evaluation, today announced that they have ...
... Presented Results at The Sixth International Symposium on Melanoma ... Detailed Efficacy Data to be Presented at ASCO May ... Provectus Pharmaceuticals, Inc. (OTC Bulletin Board: PVCT), a ... interim safety and efficacy results from the first 20 ...
Cached Medicine Technology:ICON and MedAvante Sign Alliance Agreement 2Video: Provectus PV-10 Interim Phase 2 Safety and Efficacy Results are as Good as or Better than Phase 1 Results 2Video: Provectus PV-10 Interim Phase 2 Safety and Efficacy Results are as Good as or Better than Phase 1 Results 3Video: Provectus PV-10 Interim Phase 2 Safety and Efficacy Results are as Good as or Better than Phase 1 Results 4
(Date:7/2/2015)... VA (PRWEB) , ... July 02, 2015 , ... sweetFrog ... Texas. The opening is now the 19th sweetFrog store located in the Lone Star ... list of fastest growing companies in 2014. , The store, which opened July 1 ...
(Date:7/2/2015)... ... ... swing, Americans are flocking to Canada’s many lakes to reel in their fair share of ... it’s easy to understand why. From the Pacific Northwest Coast of British Columbia to the ... huge industry, and Americans make up the vast majority of anglers from outside of Canada. ...
(Date:7/2/2015)... ... July 02, 2015 , ... Global leader and compression innovator, SIGVARIS ... for men. , For style that’s quick on its feet, men will love ... great news for men everywhere because a simple change in socks can dramatically help ...
(Date:7/2/2015)... TX (PRWEB) , ... July ... ... pressure wound therapy (NPWT) - pipeline review 2015” provides comprehensive information on ... of development. Complete report on negative pressure wound therapy (NPWT) with 22 ...
(Date:7/2/2015)... ... July 02, 2015 , ... Breakthrough technologies ... pain treatment. Dr. Lev Kalika, founder of New York Dynamic Neuromuscular Rehabilitation ... on the conservative treatment of back, hip, knee and shoulder pain as well ...
Breaking Medicine News(10 mins):Health News:sweetFrog Expands Texas Footprint with Location in Canton 2Health News:SIGVARIS Kicks Up Its Style for Men with the Launch of MIDTOWN MICROFIBER in a Dark Navy Stripe Pattern 2Health News:SIGVARIS Kicks Up Its Style for Men with the Launch of MIDTOWN MICROFIBER in a Dark Navy Stripe Pattern 3Health News:Negative Pressure Wound Therapy (System, Wound Care, Tissue Cooling NPWT) Pipeline Review 2015 Market Research Report Available at RnRMarketResearch.com 2Health News:Negative Pressure Wound Therapy (System, Wound Care, Tissue Cooling NPWT) Pipeline Review 2015 Market Research Report Available at RnRMarketResearch.com 3Health News:Negative Pressure Wound Therapy (System, Wound Care, Tissue Cooling NPWT) Pipeline Review 2015 Market Research Report Available at RnRMarketResearch.com 4Health News:Breakthrough Technologies for Carpal Tunnel Treatment in New York City 2Health News:Breakthrough Technologies for Carpal Tunnel Treatment in New York City 3Health News:Breakthrough Technologies for Carpal Tunnel Treatment in New York City 4
... Calif., March 31 Alexza,Pharmaceuticals, Inc. (Nasdaq: ALXA ... financing facility under which it may sell up to ... Ltd. over a,24-month period. Alexza is not obligated to ... to enter into and consummate other equity and,debt financing ...
... occur , , MONDAY, March 31 (HealthDay News) -- Cerebral ... from red blood cells that have leaked out of ... over age 60 than previously believed, according to a ... higher overall prevalence of cerebral microbleeds compared to other ...
... WILMINGTON, N.C., March 31 PPD, Inc. (Nasdaq:,PPDI) ... as executive,vice president of global clinical development. In ... company,s Phase II-IV operations in,North America; Latin America; ... "Mike Wilkinson brings an exceptional resume with strong ...
... A Saint Louis University cardiologist called upon the U.S. ... strong warning it recently placed on a diagnostic tool, ... life-threatening cardiac events. , In October 2007, the ... agents, which are used to improve the quality of ...
... following was,issued today by the National Press Club:, National ... 2:00 p.m., National Press Club (Broadcast Center), ... will discuss,Quality as a Path to Improving the Cost of ... patient safety and health care products and,services company, R. Kerry ...
... By Will Arnett, Matthew Broderick, Steve Carell, Stephen, ... Kevin James,Conan O,Brien, Rosie O,Donnell, Amy Poehler, Adam Sandler, ... The Insult Comic Dog And Many More To Be ... announced today that,Kelsey Grammer, Ben Stiller, Grammy Award-winning band ...
Cached Medicine News:Health News:Alexza Secures $50 Million Committed Equity Financing Facility With Azimuth Opportunity, Ltd. 2Health News:Alexza Secures $50 Million Committed Equity Financing Facility With Azimuth Opportunity, Ltd. 3Health News:Alexza Secures $50 Million Committed Equity Financing Facility With Azimuth Opportunity, Ltd. 4Health News:Small Brain Lesions More Common Than Thought in Those Over 60 2Health News:PPD Names Mike Wilkinson Executive Vice President of Global Clinical Development 2Health News:PPD Names Mike Wilkinson Executive Vice President of Global Clinical Development 3Health News:New research shows benefits of ultrasound contrast agents outweigh potential risk to heart patients 2Health News:New research shows benefits of ultrasound contrast agents outweigh potential risk to heart patients 3Health News:Kelsey Grammer, Ben Stiller, Maroon 5 and The Roots Added to COMEDY CENTRAL's(R) Live On-air Charity Special 'Night of Too Many Stars: An Overbooked Concert for Autism Education' Hosted by Jon Stewart on Sunday April 13, at 8 p.m. ET 2
Biotest ELPHA (=Enzyme Linked Probe Hybridization Assay) for class I and class II HLA typing shows convincing advantages for your lab routine....
This ELISA test is used for the detection and semi-quantitation of lgG antibobies to proteinase 3(pr3) in human sera, as an aid to the diagnosis of wegener s granulomatosis....
... for the semi-quantitative determination of specific ... serum. The results of the anti-GBM.assay ... in the diagnosis of diseases associated ... including Goodpastures Syndrome. Levels of these ...
The assay is an immunometric ('sandwich') EIA for the quantitative measurement of LH in human serum or plasma. LH in the sample is bound by 2 monoclonal anti-LH antibodies directed at different epito...
Medicine Products: